Navigation Links
International Drug & Explosives Detection Company Identa Corp Reports on New USA Marketing Representative
Date:7/9/2010

JERUSALEM, Israel, July 9, 2010 /PRNewswire-FirstCall/ -- IDenta Corp. (PINKSHEETS: IDTA) CEO Yaacov Shoham today issued a statement on the results of the three day meeting between executives of Identa Corp and the new United States representative for marketing of Identa products.

Mr. Shoham stated, "We have just concluded nine hours of intensive meetings each day for three days with our new representative in USA, and have established a detailed marketing plan to get Identa to the right position in the United States different markets. We have been able to take the information supplied by the former rep. Jant Pharmacal and analyze it and we have established an aggressive detailed marketing plan (with mile stones) on how to continue the penetration into the different American markets.

Based on the new reps background (30 years in American marketing, especially in the military and home land security) and his many successes in the relevant markets, we at Identa feel that we will be able to move ahead with our goals in a reasonable period. Finally we understand that we have found the right "partner" in the American markets."

Mr. Shoham further stated, "Both sides (Identa and the new rep) are committed to the new goals and will invest all the time, energy, money etc. to reach these goals in the first 3-year agreement. The new rep will be busy most of the time only with the Identa's different products. We have decided that everything will be done in day per day connections, and in a full transparency. We at Identa know that we have the best and most advance products on the market, and we need to make everything possible to make them very well known in the American markets. We are committed to getting the Identa name out to all sectors (public and private) of the American market. We want to make Identa a "household" word."

Information concerning IDenta's entire product line may be found at http://www.IDenta.biz

ABOUT IDENTA

Since 2003, IDenta Corporation has been recognized as a worldwide leader in the development of proprietary on-site drug, drug precursor and explosive detection kits. IDenta develops, manufactures and distributes products for both the professional and civil markets which consistently pass the highest qualifications and testing procedures of law enforcement and security agencies around the world.

DISCLAIMER

Certain of the statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements" that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management's expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.

For Investor Relations, lobbying interests or information concerning IDenta's products internationally or the development of new chemical detectors, contact: Yaacov Shoham, IDenta Corp., CEO, Tel: +972-52-6554487, fpi@drugsdetector.com, http://www.identa.biz.

    Contact:
    Yaacov Shoham
    IDenta Corp.
    CEO
    Tel: +972-52-6554487
    fpi@drugsdetector.com
    http://www.identa.biz
    mailto:fpi@drugsdetector.com



'/>"/>
SOURCE IDenta Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... PLANO, Texas , April 20, 2017  Vivify ... via mobile devices, has been awarded a very significant ... care via EMRs to continual care via digital health. ... of key intellectual property and further secures Vivify,s position ... Vivify, launched in 2009, was the first company to ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... process has been in place since the RBMA was founded in 1968 with all ... Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... of America (UCAOA) and College of Urgent Care Medicine will host industry leaders ... sessions and speakers will help those in the industry adapt to the issues ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to accept ... a hearing aid doesn’t have the stigma it had when great-grandpa wore his hearing ... Greater Boston, in a NALA North American Speaker Series (NASS) segment. “He ...
(Date:4/28/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a ... does not. Yisrayl says with so many titles and names for the Creator, it’s ... with a little Scripture, backed with a lot of research, the truth is undeniable. ...
Breaking Medicine News(10 mins):